UNSPSC 51333108: Etazolate hydrochloride

This classification denotes an anxiolytic with the molecular formula C14H19N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YO3254Y6B, chemically known as 1h-pyrazolo(3,4-b)pyridine-5-carboxylic acid, 1-ethyl-4-((1-methylethylidene)hydrazino)-, ethyl ester but more generally known as etazolate hydrochloride, which bears US NIH Compound Identifier 3277. Most nations, for tariff and trade purposes, schedule etazolate hydrochloride under HS 29339990 and SITC 51577.

As of Q4 2014, ETAZOLATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etazolate hydrochloride bears US NLM identifiers UMLS ID C0917853 and NCI Concept Code C72768. SMILES: CCN1C2C(CN1)C(C(CN2)C(=O)OCC)NN=C(C)C.CL.

UNSPSC 51333108 Etazolate hydrochloride is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, but recent activity shows a mismatch between the code's nominal scope and what state and local governments are actually buying under it. The three most recent solicitations tagged to this code include Seminole County, Florida procuring naloxone and drug deactivation systems; the Texas Health and Human Services Commission issuing a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishing statewide contracts for generic multi-source pharmaceuticals and over-the-counter products. None of these opportunities directly target etazolate hydrochloride. The issuing bodies span county health departments (Seminole County), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP, which serves state and local jurisdictions across Minnesota and Oregon). State agencies and cooperative purchasing alliances dominate the mix.

Activity concentrates in the South and Midwest, with Seminole County, Florida; Texas; Minnesota; and Oregon represented in recent postings. Seminole County's IFB 60459723LAS, due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; this is a straightforward product procurement with a two-year initial term and one-year renewal option. Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, is exploratory market intelligence gathering on direct-to-manufacturer prescription capabilities rather than a binding solicitation. MMCAP's RFP S1070000015802, due March 26, 2026, establishes multistate pharmaceutical contracts with pricing evaluated on fixed cost (10 percent), administrative compliance (5 percent), EDI capability (5 percent), administrative fee agreement (5 percent), and price competitiveness (75 percent); the contract runs two years with optional extensions, and all products must achieve marketplace availability by May 15, 2026. The code shows little relevant recent activity for etazolate hydrochloride specifically; current state and local procurement under this tag focuses on broader pharmaceutical categories and direct-to-consumer drug programs rather than this specific active pharmaceutical ingredient.